First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist in development for the treatment of Tourette syndrome.
Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization
Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational therapy in development for the treatment of Tourette syndrome.
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Emalex Biosciences announced positive topline data from its Phase 3 registrational study of ecopipam, a novel dopamine-1 receptor antagonist, in subjects with Tourette syndrome.
Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate
An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of treatment.
